Rare disease focus La Jolla Labs specializes in high-throughput screening for rare disease drug discovery, presenting a clear opportunity to offer specialized screening, assay development, and HTS optimization services or partnerships to accelerate their pipeline.

HTS software They are developing hts.bio, a cloud-based software tool for designing, executing, and analyzing large high-throughput experiments. This suggests potential for collaboration on software licenses, data management solutions, cloud scalability, and analytics add-ons.

Cloud and security Their tech stack includes Google Cloud, CDN, Envoy, Sentry, and security-oriented measures (HSTS) indicating openness to cloud-native solutions, data protection, and scalable infrastructure enhancements.

Small team, niche market With 2-10 employees and revenue in the low millions, they are a nimble, high-potential client likely to value end-to-end support, cost-effective pilot programs, and strategic partnerships to accelerate growth.

Comparable landscape Operating in a biotech ecosystem with peers like QIAGEN and Illumina signals competitive potential for collaborations or vendor relationships in assay platforms, instrumentation integration, and strategic distribution or co-development arrangements.